TrialJournal of hematology & oncology2025

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).

Hua-Jun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.